Gainers & Losers
Mon Nov 25 2024 10:23:34- Larsen & Toubro share price
- ₹3,753.254.13%
- State Bank Of India share price
- ₹844.753.52%
- HDFC Bank share price
- ₹1,784.602.21%
- Wipro share price
- ₹582.751.99%
- ICICI Bank share price
- ₹1,301.501.82%
Active Stocks
Mon Nov 25 2024 10:27:51- Adani Power share price
- ₹446.85-3.02%
- Power Grid Corporation Of ...
- ₹342.851.74%
- Tata Steel share price
- ₹143.600.56%
- State Bank Of India share price
- ₹844.753.52%
- HDFC Bank share price
- ₹1,784.602.21%
Business News/Market/Market Stats/Alembic Pharmaceuticals share price/ Alembic Pharmaceuticals Profit Loss Annual
Alembic Pharmaceuticals Profit & Loss Annual
Trade1,096.95 +55.15 (5.29%)Updated : 25 Nov 2024
| Fiscal Period | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
| Revenue | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 |
| Total Revenue | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 |
| Costof Revenue Total | 1,715.08 | 2,174.70 | 1,844.03 | 1,639.99 |
| Gross Profit | 4,513.55 | 3,477.92 | 3,461.76 | 3,753.14 |
| Selling/ General/ Admin Expenses Total | 1,446.29 | 2,178.21 | 1,945.86 | 1,745.86 |
| Depreciation/ Amortization | 272.67 | 275.43 | 286.78 | 183.47 |
| Other Operating Expenses Total | 2,133.91 | 17.55 | 12.67 | 8.41 |
| Total Operating Expense | 5,567.95 | 5,214.82 | 4,718.33 | 4,096.30 |
| Operating Income | 660.68 | 437.80 | 587.46 | 1,296.83 |
| Interest Inc( Exp) Net- Non- Op Total | -561.90 | -491.80 | 311.80 | 691.20 |
| Other Net | 28.31 | 1.58 | 0.93 | 0.74 |
| Net Income Before Taxes | 632.80 | 385.50 | 620.11 | 1,368.08 |
| Provisionfor Income Taxes | 16.00 | 12.61 | 104.46 | 253.32 |
| Net Income After Taxes | 616.80 | 372.89 | 515.65 | 1,114.76 |
| Equity In Affiliates | -9.80 | -309.20 | 52.80 | 317.40 |
| Net Income Before Extra Items | 615.82 | 341.97 | 520.93 | 1,146.50 |
| Net Income | 615.82 | 341.97 | 520.93 | 1,146.50 |
| Income Availableto Com Excl Extra Ord | 615.82 | 341.99 | 520.94 | 1,146.50 |
| Income Availableto Com Incl Extra Ord | 615.82 | 341.99 | 520.94 | 1,146.50 |
| Diluted Net Income | 615.82 | 341.99 | 520.94 | 1,146.50 |
| Diluted Weighted Average Shares | 19.66 | 19.66 | 19.66 | 19.37 |
| Diluted EPS Excluding Extra Ord Items | 31.33 | 17.40 | 26.50 | 59.18 |
| DPS- Common Stock Primary Issue | 11.00 | 8.00 | 10.00 | 14.00 |
| Diluted Normalized EPS | 31.33 | 17.63 | 26.48 | 59.12 |
| Research Development | - | 5,689.30 | 6,289.90 | 5,185.70 |
| Unusual Expense( Income) | - | 0.00 | - | - |
| Gain( Loss)on Saleof Assets | - | -47.00 | 5.40 | 13.90 |
| Total Adjustmentsto Net Income | - | 0.20 | 0.10 | - |
*All figures in crores except per share values
Alembic Pharmaceuticals Quick Links
Alembic Pharmaceuticals Dividend Alembic Pharmaceuticals Bonus Alembic Pharmaceuticals News Alembic Pharmaceuticals AGM Alembic Pharmaceuticals Rights Alembic Pharmaceuticals Splits Alembic Pharmaceuticals Board Meetings Alembic Pharmaceuticals Key Metrics Alembic Pharmaceuticals Shareholdings Alembic Pharmaceuticals Balance Sheet Alembic Pharmaceuticals Cashflow Alembic Pharmaceuticals Q1 Results Alembic Pharmaceuticals Q2 Results Alembic Pharmaceuticals Q3 Results Alembic Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
3,753.25+148.70(4.13%)
844.75+28.70(3.52%)
1,784.60+38.65(2.21%)
1,733.95-13.75 (-0.79%)
2,460.60-18.40 (-0.74%)